.jpg)
Euronext today welcomed Inventiva, a biopharmaceutical company specialised in the development of new therapies, particularly for fibrotic diseases, to Compartment C of its regulated market in Paris.
Inventiva was founded in 2012 and delivers innovative therapies that interact with nuclear receptors, transcription factors and epigenetic modulators. The company is working to open up novel breakthrough therapies for fibrotic diseases, cancers, and orphan diseases with substantial unmet medical needs. It has over 100 highly qualified employees and owns state-of-the-art R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. It also owns a proprietary chemical library of over 240,000 molecules, as well as integrated biology, chemistry, ADME and pharmacology platforms. Today Inventiva has three projects in particular, all at an advanced stage, in markets targeted by big companies, with two phase IIb clinical studies for NASH[1] and systemic sclerosis—and one phase I/II study for the treatment of Maroteaux-Lamy syndrome (MPS VI).
Inventiva (ticker code: IVA) was listed through the admission to trading on 15 February 2017 of a total of 15,681,240 shares including 5,651,240 new shares issued through a Global Offering[2], after the partial exercise of the extension option and before the potential exercise of the over-allotment option.
The offering price was set at €8.50 per share. Inventiva’s market capitalisation on the day of listing was €133 million, and the transaction raised a total of €48 million.
Inventiva joins the 52 biotechnology companies already listed on Euronext markets, which together represent a total capitalisation of €13.8 billion. In just a few years Euronext has become the European benchmark for life science businesses, and promotes the segment’s visibility with its recently launched Biotech Barometer.
At the listing ceremony, Frédéric Cren, Chairman & CEO and co-founder of Inventiva, said, “We are delighted to list in Compartment C on Euronext Paris—a key stage in our company’s development. The funding raised today will allow us to secure additional resources to finance our business and continue to expand our technology platforms, collaborations, and drug candidates. We are very proud to join Europe’s standard-setting exchange for biotechnology companies, a move that has expanded our shareholder base to both individuals and large US and European funds specialised in life sciences.”
